$vnda

Vanda Pharmaceuticals' Bysanti treatment for Bipolar I disorder and Schizophrenia is on the FDA radar with a PDUFA date of February 21st. Recent social posts highlight this upcoming decision and its potential impact on the company's stock.

About $vnda

Vanda Pharmaceuticals is a biopharmaceutical company focused on developing treatments for central nervous system disorders.

Insights

Engagements: [-----] (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [-----]
[--] Week: [------] +3,638%
[--] Month: [-------] -48%
[--] Months: [---------] +359%
[--] Year: [---------] -45%
1-Year High: [-------] on 2025-12-31
1-Year Low: [--] on 2025-09-15

Engagements by network (24h): Reddit: [--] X: [-----] YouTube: [--]

Mentions: [--] (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
[--] Month: [--] -24%
1-Year High: [---] on 2025-11-19
1-Year Low: [--] on 2025-09-14

Mentions by network (24h): Reddit: [--] X: [--] YouTube: [--]

Creators: [--] (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning $vnda in the last [--] hours which is down 63% from [--] in the previous [--] hours Daily Average: [--]
[--] Month: [--] -25%
1-Year High: [---] on 2025-11-19
1-Year Low: [--] on 2025-09-14

The most influential creators that mention $vnda in the last [--] hours

Creator Rank Followers Posts Engagements
@BiopharmIQ [--] [------] [--] [---]
@MiriamF24887120 [--] [--] [--] [--]
@WolfOfPathogens [--] [--] [--] [--]
@ElMonoGran42994 [--] [---] [--] [--]

View More

Sentiment: 50%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: 50%
Daily Average: 81%
[--] Month: 29% -46%
[--] Months: 29% -71%
[--] Year: 29% -71%
1-Year High: 100% on 2025-02-18
1-Year Low: 12% on 2025-11-11

Most Supportive Themes:

Most Critical Themes:

Top $vnda Social Posts

Top posts by engagements in the last [--] hours

Showing a maximum of [--] top social posts without a LunarCrush subscription.

"Latest catalysts: $VNDA Catalyst Date - 2026-02-21 Drug - Bysanti Treatment - Bipolar I disorder Schizophrenia Poa : 75% https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"
X Link @Biopharma_Watch 2026-02-16T15:45Z [----] followers, [---] engagements

"$RGNX -15% 🔴 FDA issued a CRL for RGX-121 in MPS II / Hunter syndrome ⚠ Key issues: pt selection external control comparability and CSF biomarker not accepted as surrogate. ❌ No approval; FDA suggests more data/new study. Plans BLA resubmission. See image for details. February Biotech PDUFA Pulse: 📡 Whats on the FDA Radar Feb [--] $RGNX RGX-121 (MPS II / Hunter syndrome) Priority Review Feb [--] $MRK Keytruda (platinum-resistant recurrent ovarian cancer) Priority Review (label expansion) Feb [--] $VNDA Bysanti (bipolar I disorder https://t.co/jRQJdkbvdw February Biotech PDUFA Pulse: 📡 Whats on"
X Link @BiopharmIQ 2026-02-10T17:40Z 28.9K followers, [----] engagements

"February Biotech PDUFA Pulse: 📡 Whats on the FDA Radar Feb [--] $RGNX RGX-121 (MPS II / Hunter syndrome) Priority Review Feb [--] $MRK Keytruda (platinum-resistant recurrent ovarian cancer) Priority Review (label expansion) Feb [--] $VNDA Bysanti (bipolar I disorder / schizophrenia) Feb [--] $ETON ET-600 (central diabetes insipidus) Feb [--] $ASND TransCon CNP (achondroplasia) Priority Review Feb [--] $BMRN PALYNZIQ (PKU adolescents) Priority Review (label expansion) See the attached graphic for the full February PDUFA calendar. https://twitter.com/i/web/status/2016215337554083884"
X Link @BiopharmIQ 2026-01-27T18:22Z 28.9K followers, 107.1K engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing